The Executive VP & Chief Information Officer of Bristol-Myers Squibb Company (NYSE:BMY), Paul von Autenried, Just Sold 45% Of Their Holding

Some Bristol-Myers Squibb Company (NYSE:BMY) shareholders may be a little concerned to see that the Executive VP & Chief Information Officer, Paul von Autenried, recently sold a substantial US$2.9m worth of stock at a price of US$57.18 per share. That's a big disposal, and it decreased their holding size by 45%, which is notable but not too bad.

View our latest analysis for Bristol-Myers Squibb

The Last 12 Months Of Insider Transactions At Bristol-Myers Squibb

Notably, that recent sale by Paul von Autenried is the biggest insider sale of Bristol-Myers Squibb shares that we've seen in the last year. That means that an insider was selling shares at around the current price of US$56.81. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

Insiders in Bristol-Myers Squibb didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Bristol-Myers Squibb insiders own about US$112m worth of shares (which is 0.09% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

What Might The Insider Transactions At Bristol-Myers Squibb Tell Us?

An insider sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Bristol-Myers Squibb. For example - Bristol-Myers Squibb has 3 warning signs we think you should be aware of.

But note: Bristol-Myers Squibb may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.